Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Three-drug combo promising against high-risk CLL

Key clinical point: A three-drug combination may improve response rates in high-risk CLL.

Major finding: The CR/CRi rate was 58.5%.

Study details: Prospective open-label phase 2 trial in 41 patients with CLL with del(17p) and/or TP53 mutations.

Disclosures: The trial was supported by Janssen-Cilag and Roche. Dr. Huber disclosed travel reimbursement from Novartis. Dr. Danilov disclosed consulting for AbbVie, Janssen, and Genentech.


Huber H et al. EHA Congress. Abstract S157.